Observational Retrospective and Prospective Study on the Treatment of Femoral Fractures With EBA2
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01599221|
Recruitment Status : Unknown
Verified May 2012 by Citieffe S.r.l.
Recruitment status was: Active, not recruiting
First Posted : May 15, 2012
Last Update Posted : September 11, 2012
This is an observational, retrospective and prospective study where subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures will be followed for data collection since the day before their surgery (retrospectively) until day 180 after surgery (retrospectively and prospectively).
This study is aimed at collecting data from patients who have already been treated with EBA2 nail. Data collection will cover the details of the fracture and surgery (from which the retrospective nature of the study), as well as details of follow up visits after surgery that patients routinely carry out up to 6 months (from which the prospective nature of the study).
The study will be conducted in three clinical sites in Italy.
|Condition or disease||Intervention/treatment|
|Femoral Fractures||Device: EBA2|
EBA2, the technological evolution of Endovis BA, is now available. The device was developed in conformity with Regulations 93/42/CE and 2007/47/CE, it has the CE trademark and it is registered in the Italian National Registry of Medical Devices. EBA2 has the unique features described below:
- it is undersized compared to other nails in commerce, both proximal and distal, to further facilitate the insertion into the bone. The undersizing is aimed to reduce the stiffness of the stem. In particular, the biological nail-bone interaction will be improved as a consequence of lower shear stresses on the frontal plane;
- it is made entirely of titanium. The choice of such a material is aimed to create a flexible means of synthesis that minimizes the differences with the healthy bone mechanical properties and reduces complications in the process of fracture healing;
- it is a dual-lag screw system that provides appropriate guidance to the sliding of the fractured extremities and an improved stability. It is effective to limit torsional instability of the femoral head, both during the intervention, by the action of tightening of the screw itself, and during the healing period due to improved bearing capacity towards multidirectional loads;
- the associated surgical instruments are simple; the low number of pieces and their ease of use made the success even of the previous version.
The aim of the present observational study is to collect data that confirm for EBA2, the technological evolution of Endovis BA, the performance and tolerability proved in the previous trial. In addition, given the increasing importance that good quality of life represents in elderly, objective of this observational study is to verify the general satisfaction of the patient with lateral proximal femoral fractures treated with EBA2.
In order to evaluate subject's walking ability after the surgical insertion of EBA2, only subjects who could walk independently before of the fracture will be included in this observational study.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Observational Retrospective and Prospective Study on the Treatment of Lateral Proximal Femoral Fractures With Medical Device EBA2|
|Study Start Date :||March 2012|
|Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||October 2012|
Subjects with EBA2
Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
Other Name: Endovis B.A.
- EBA2 performance at day 90 [ Time Frame: Day 90 ]
As a first primary endpoint, EBA2 performance will be assessed at 90 days. The performance will be assessed on the basis of failures, complications and malfunctioning related to the device.
Since a centralized review will be performed, the extent of agreement between raters will be assessed using both Kappa statistic and AC1-statistic. Any discrepancy on the X-ray evaluation will be discussed between the raters and possibly with the Sponsor.
- EBA2 performance at day 180 [ Time Frame: Day 180 ]EBA2 performance will also be assessed at 180 days. The performance will be assessed on the basis of failures, complications and malfunctioning related to the device.
- EBA2 performance at day 30 (optional primary endpoint) [ Time Frame: Day 30 ]EBA2 performance will be optionally assessed at 30 days. The performance will be assessed on the basis of failures, complications and malfunctioning related to the device.
- SF12 Questionnaire [ Time Frame: Day 30 (optional), 90 and 180 ]The SF12 Questionnaire routinely administered to patients, will be used to assess the subjective general satisfaction of patients treated with EBA2 at day 30 (optional), 90 and 180.
- Clinical evaluation of pain [ Time Frame: Day 30 (optional), 90 and 180 ]Clinical evaluation of pain data will be collected at day 30 (optional), 90 and 180 and summarized in a 4-point scale (no pain, mild, moderate, unbearable).
- Radiographic examination [ Time Frame: Day 30 (optional), 90 and 180 ]The reduction maintenance, the fracture consolidation and the callus formation will be assessed through radiographic examination at day 30 (optional), 90 and 180. Frequencies and percentages will be calculated at each time point.
- Walking ability data [ Time Frame: Day 30 (optional), 90 and 180 ]Walking ability data will be collected at day 30 (optional), 90 and 180 and summarized in a 3-point scale (not walking, walking with support, walking without support).
- Device-related adverse events [ Time Frame: Up to day 180 ]Device-related adverse events reported during the study will be described using frequency and percentage and coded according to MedDRA coding (version 13). The number and percentage of subjects with at least one device-related adverse event will be showed. The frequency of events by SOC (System Organ Class) and PT (Preferred Term) will be reported. The characteristics of the events occurring to subjects (severity, duration, outcome, etc.) will also be summarized. The events will also be described by nature of device failure or malfunctioning.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01599221
|Azienda Ospedaliero-Universitaria Consorziale Policlinico|
|Bari, Italy, 70124|
|Unità operativa complessa di Ortopedia e Traumatologia - AUSL 12 di Viareggio|
|Lido di Camaiore, Italy|
|S.C. Ortopedia e Traumatologia - P.O. Centrale SS. Annunziata|
|Taranto, Italy, 74100|
|Principal Investigator:||Vincenzo Caiaffa, MD||S.C. Ortopedia e Traumatologia - P.O. Centrale "SS. Annunziata" ASL Taranto - Italy|